<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672487</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD095587</org_study_id>
    <nct_id>NCT03672487</nct_id>
  </id_info>
  <brief_title>Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age</brief_title>
  <acronym>BETTY</acronym>
  <official_title>Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Public Health and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute for Clinical Effectiveness and Health Policy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are proposing to perform a double-blinded, non-inferiority randomized
      controlled trial comparing a short 30-day treatment with BZN 150mg/day (30d/150mg) vs. a
      60-day treatment with BZN 300 mg/day (60d/300mg). The investigators will recruit not
      previously treated T. cruzi seropositive women with a live birth during the postpartum period
      in Argentina, randomize them at six months postpartum, and follow them up with the following
      specific aims:

      Specific Aim 1: To measure the effect of BZN 30d/150mg compared to 60d/300mg preconceptional
      treatment on parasitic load measured by the frequency of positive PCR (primary outcome) and
      by real-time quantitative PCR (qPCR), immediately (Specific Aim 1a) and 10 months (Specific
      Aim 1b) after treatment.

      Hypothesis 1a: The frequency of positive PCR and the parasitic load measured by qPCR
      immediately after BZN 30d/150mg will be non-inferior (Non Inferiority [NI] margin for PCR:
      10% absolute difference) to BZN 60d/300mg.

      Hypothesis 1b: The frequency of positive PCR and the parasitic load measured by qPCR 10
      months after BZN 30d/150mg will be non-inferior (NI margin for PCR: 9% absolute difference)
      to BZN 60d/300mg.

      Specific Aim 2: To measure the frequency of serious adverse events leading to treatment
      interruption of BZN 30d/150mg compared to 60d/300mg.

      Hypothesis 2: The frequency of serious adverse events leading to treatment interruption will
      be 50% lower with BZN 30d/150mg than with BZN 60d/300mg.

      A 24-month recruitment period is planned in four hospitals with 23,436 deliveries in 2015 and
      frequencies of T. cruzi seropositive women varying from 1.5% to 4.8%. The investigators are
      planning to enroll 600 T. cruzi seropositive women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of positive PCR and the parasitic load measured by qPCR immediately after BZN 30d/150mg</measure>
    <time_frame>30 days for the 30d course arm, and 60 days for the 60d course arm</time_frame>
    <description>The frequency of positive PCR and the parasitic load measured by qPCR immediately after BZN 30d/150mg will be non-inferior (Non Inferiority [NI] margin for PCR: 10% absolute difference) to BZN 60d/300mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The frequency of positive PCR and the parasitic load measured by qPCR 10 months after BZN 30d/150mg</measure>
    <time_frame>10 months from the end of the 60d treatment</time_frame>
    <description>The frequency of positive PCR and the parasitic load measured by qPCR immediately after BZN 30d/150mg will be non-inferior (Non Inferiority [NI] margin for PCR: 10% absolute difference) to BZN 60d/300mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of serious adverse events leading to treatment interruption of BZN 30d/150mg compared to 60d/300mg immediately after BZN 30d/150mg</measure>
    <time_frame>60 days after treatment initiation</time_frame>
    <description>The frequency of serious adverse events leading to treatment interruption will be 50% lower with BZN 30d/150mg than with BZN 60d/300mg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Chagas Disease</condition>
  <arm_group>
    <arm_group_label>60/300mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). The investigators will purchase the drug at full cost.
Interventions: The standard 60d course will be 300 mg per day, which is similar to the dose used in the second phase of the BENEFIT trial. The drug will be administered orally in two doses per day: the standard course will be one 100mg and one 50mg tablet in the morning and in the evening for 60 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30/150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will use a preparation of benznidazole (BZN) that is commercially available in Argentina: Abarax® 100mg and 50mg tablets from ELEA laboratories (Buenos Aires, Argentina). ELEA laboratories will prepare the placebo oral tablets, which will be identical to the drug tablets in aspect and taste. The investigators will purchase the drug and placebo at full cost.
Interventions: The BZN short course low dose scheme will be 150 mg per day for 30 days. The drug will be administered orally in two doses per day: the short course treatment will start with the active drug and then placebo oral tablet; one 100 mg tablet and one placebo tablet in the morning and one 50 mg tablet and one placebo tablet in the evening for the first 30 days. The last 30 days will be two placebo tablets in the morning and the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>Benznidazole tablet</description>
    <arm_group_label>30/150mg</arm_group_label>
    <arm_group_label>60/300mg</arm_group_label>
    <other_name>Abarax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Sugar pill manufactured to mimic Benznidazole</description>
    <arm_group_label>30/150mg</arm_group_label>
    <other_name>Placebo (for Benznidazole)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent from the mother.

          -  T. cruzi seropositivity confirmed by at least two positive tests.

          -  Live birth.

        Exclusion Criteria:

          -  Women residing outside of the provinces of Chaco, Santiago del Estero, or Tucumán.

          -  Previous trypanocide treatment (BZN or nifurtimox).

          -  Female sterilization; no intention to use modern contraception methods during
             treatment.

          -  Positive pregnancy test.

          -  History of severe alcohol abuse within two years; renal insufficiency.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women of childbearing age</gender_description>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Buekens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Buekens, MD, PhD</last_name>
    <phone>5049888803</phone>
    <email>pbuekens@tulane.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fernando Althabe, MD, MSc</last_name>
    <phone>+54 11 4777-8767</phone>
    <email>falthabe@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane School of Public Health and Tropical Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Clinical Effectiveness and Health Policy</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Althabe, MD, MSc</last_name>
      <email>falthabe@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Althabe, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Luisa Cafferata, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eduardo Bergel, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mabel Berrueta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Belizan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergio Sosa-Estani, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Schijman, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>September 13, 2019</last_update_submitted>
  <last_update_submitted_qc>September 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital Transmission</keyword>
  <keyword>Trypanosoma cruzi</keyword>
  <keyword>Benznidazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03672487/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

